Basic Information
Zedira is a privately held clinical-stage biopharmaceutical company focused on diseases in the fields of celiac disease and other autoimmune, fibrotic, and thrombotic conditions related to transglutaminase. The company develops, manufactures, and sells specialty reagents and kits for research and clinical diagnostics. Based on a series of patented synthetic transglutaminase blockers, Zedira has established a pipeline of drug candidates tailored to specific indications. ZED1227 is the first direct-acting transglutaminase inhibitor in clinical development.